3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
19
Gynecologic
3
Genitourinary
3
Breast
3
Thoracic
2
Gastrointestinal
2
Dermatologic
2
Sarcoma
1
Other solid neoplasm
1
Conditions
Sarcoma
8
Melanoma
3
Hemangiosarcoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Leiomyosarcoma
2
Carcinosarcoma
2
Carcinoma, Endometrioid
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liposarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangioendothelioma, Epithelioid
1
Interventions
pembrolizumab
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
Fluorouracil
4
Filgrastim
4
Cetuximab
3
fludarabine
2
cemiplimab
2
belinostat
2
atezolizumab
2
Temozolomide
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Nivolumab
2
Ipilimumab
2
Cyclophosphamide
2
Bortezomib
2
AH 111585
2
zanidatamab
1
vocimagene amiretrorepvec
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
spartalizumab
1
seribantumab
1
selpercatinib
1
repotrectinib
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
durvalumab
×
Sarcoma
×
Clear all
NCT02423863
2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2
Completed
26 enrolled